Since we found higher levels of IL-1α in the plasma and CSF of SS rats, we investigated the effect of systemic treatment with IL-1RA (10 mg/kg, i.p.), an antagonist of the IL-1 receptor at which IL-1α acts27, on the SS hyperalgesic phenotype (Fig. 2c). Here, IL1A is linked to synovial sarcoma.